During growth within the sand fly and within axenic culture, Leishmania promastigotes undergo differentiation from a dividing non-infective stage to a resting infective or metacyclic stage which is uniquely adapted for life in the vertebrate. The culture conditions which promote differentiation of parasites to an infective stage have now been optimized for various strains. This development is accompanied by a substantial modification of the surface lipophosphoglycan (LPG) which is the major surface glycoconjugate of these cells. The developmental modifications include an elongation of the molecule due to a 2-3 fold increase in the number of phosphorylated oligosaccharated units expressed, and a change in the composition of some of these units. In the case of L. major and L. donovani the structural polymorphism is expressed as a loss of terminal galactose residues on the LPG. Related structural changes have now been confirmed for L. amazonensis and L. infantum. The substitution or capping of terminally exposed sugars with other sugar residues was shown to be the molecular mechnism underlying the attachment and release of promastigotes from midgut epithelial cells during their development in the fly. The specific oligosaccharide units which mediate the binding have now been identified. The species specificity of these terminal sugars appears to influence the species specificity of vectorial capacity observed in nature. LPG has been successfully used to probe for the lectin like receptors in the sand fly gut. In related studies, it was found that the presence of anti-LPG antibodies within an infective bloodmeal inhibited the development of transmissible infections within the sand fly midgut. This inhibition was only apparent when the bloodmeal also contained anti-leishmanial antibodies present in chronic infection sera.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000256-11
Application #
3790700
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
1992
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Cheung, Amy; Sacks, Diane; Dewa, Carolyn S et al. (2008) Pediatric prescribing practices and the FDA Black-box warning on antidepressants. J Dev Behav Pediatr 29:213-5
Ramalho-Ortigao, J M; Kamhawi, S; Joshi, M B et al. (2005) Characterization of a blood activated chitinolytic system in the midgut of the sand fly vectors Lutzomyia longipalpis and Phlebotomus papatasi. Insect Mol Biol 14:703-12
Kamhawi, Shaden; Ramalho-Ortigao, Marcelo; Pham, Van M et al. (2004) A role for insect galectins in parasite survival. Cell 119:329-41
Turco, Salvatore J; Sacks, David L (2003) Control of Leishmania-sand fly interactions by polymorphisms in lipophosphoglycan structure. Methods Enzymol 363:377-81
Burchmore, Richard J S; Rodriguez-Contreras, Dayana; McBride, Kathleen et al. (2003) Genetic characterization of glucose transporter function in Leishmania mexicana. Proc Natl Acad Sci U S A 100:3901-6
Spath, Gerald F; Lye, Lon-Fey; Segawa, Hiroaki et al. (2003) Persistence without pathology in phosphoglycan-deficient Leishmania major. Science 301:1241-3
Joshi, Phalgun B; Kelly, Ben L; Kamhawi, Shaden et al. (2002) Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor. Mol Biochem Parasitol 120:33-40
Sacks, D L (2001) Leishmania-sand fly interactions controlling species-specific vector competence. Cell Microbiol 3:189-96
Sacks, D; Kamhawi, S (2001) Molecular aspects of parasite-vector and vector-host interactions in leishmaniasis. Annu Rev Microbiol 55:453-83
Valenzuela, J G; Belkaid, Y; Garfield, M K et al. (2001) Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med 194:331-42

Showing the most recent 10 out of 11 publications